Myc-associated zinc finger protein: A “double-edged sword” in the malignant process of tumors

Myc-associated zinc finger protein (MAZ), a cysteine2-Histidine2 (C2H2)-type zinc finger transcription factor, is widely expressed in human tissues and frequently dysregulated in various malignancies, positioning it as a promising target for cancer therapy. MAZ exerts dual regulatory effects on gene transcription by binding to guanine-cytosine-rich (GC-rich) DNA sequences, modulating the transcription of numerous target genes. This review examines the role of MAZ in the progression of hepatocellular carcinoma, breast cancer, renal cancer, pancreatic cancer, prostate cancer, and other malignancies, with a focus on recent advancements in understanding its molecular mechanisms. These insights aim to contribute to the development of improved diagnostic and therapeutic strategies for cancer.